Author(s):
Anny Setijo Rahaju, Arifa Mustika, Priangga Adi Wiratama, Lukman Hakim, Doddy M. Soebadi
Email(s):
anny_sr@fk.unair.ac.id
DOI:
10.52711/0974-360X.2023.00214
Address:
Anny Setijo Rahaju1,2,3,4*, Arifa Mustika5, Priangga Adi Wiratama2,4, Lukman Hakim3,4,6, Doddy M. Soebadi4,6
1Doctoral Program in Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
3Universitas Airlangga Teaching Hospital, Surabaya, Indonesia.
4Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
5Divison Pharmacology and Therapy, Department of Anatomy, Histology, and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
6Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2023
Cite this article:
Anny Setijo Rahaju, Arifa Mustika, Priangga Adi Wiratama, Lukman Hakim, Doddy M. Soebadi. Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma. Research Journal of Pharmacy and Technology 2023; 16(3):1303-8. doi: 10.52711/0974-360X.2023.00214